For FY25, the company’s revenue guidance now reflects a range of $233.5M-$234.5M, representing growth of 14% to 15% over 2024 revenue. The company reiterated annual set deployment to be $15.0M and reiterated $15.0M-$17.0M of adjusted EBITDA for the full year of 2025. As of September 30, cash, cash equivalents, short-term investments and restricted cash were $59.8M, compared to $70.8M as of December 31, 2024. Free cash flow usage for the third quarter of 2025 was $3.4M, compared to $11.6M in the third quarter of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics announces FDA approval of 3P Pediatric Plating Platform
- OrthoPediatrics reports Q3 EPS (24c), consensus (26c)
- KIDS Upcoming Earnings Report: What to Expect?
- OrthoPediatrics price target lowered to $34 from $37 at Lake Street
- OrthoPediatrics price target lowered to $18 from $22 at Truist